Endocrinology & Diabetes ResearchISSN: 2470-7570

David Polidori

David Polidori
Senior Director, Translational Medicine
Janssen Research & Development, USA

Contact David Polidori


David Polidori have a background in engineering and mathemaical modeling and have been working in diabetes research for over 15 years. He was member of the Janssen team that developed canagliflozin (Invokana), the first SGLT2 inhibitor approved by the FDA for the treatment of type 2 diabetes. He is the Senior Director in translational medicine. 

Research Interest

Design and analyze clinical studies to characterize the mechanism of action and PK/PD relationships for novel pharmaceutical interventions aimed at treating cardiovascular and metabolic diseases.


Share This Page